2017_EJRNL_PP_Shashank_Shekhar_1.pdf
Terbatas Irwan Sofiyan
» ITB
Terbatas Irwan Sofiyan
» ITB
The inflammatory process plays a key role in neurodegenerative
disorder. The inflammatory molecule, 5-
lipooxygenase (5-LOX), protein is involved in the pathologic
phenotype of Alzheimer’s disease (AD) which includes A?
amyloid deposition and tau hyperphosphorylation. This study
determined the level of 5-LOX in serum of AD patients, mild
cognitive impairment (MCI) patients, and the normal elderly,
and the rescue effect by YWCS, a peptide inhibitor of 5-LOX
on neurotoxicity by A? amyloid25–35 (A?25–35) in neuroblastoma
cells. The concentration of serum 5-LOX was estimated
by surface plasmon resonance and western blot. The neuroprotective
effect of 5-LOX peptide inhibitor YWCS in A?25–
35-induced neurotoxicity was analyzed by MTT assay and
western blotting. We found significant upregulated serum 5-
LOX in AD patients and also in MCI patients compared to the
normal control group. The peptide inhibitor of 5-LOX,
YWCS, prevented the neurotoxic effect of A?25–35 by reducing
the expression of ?-secretase as well as p-Tau181 in SHSY5Y
cells. However, YWCS was nontoxic towards normal
HEK cells. The differential expression of serum 5-LOX
among the study groups suggests it can be one of potential
serum protein marker and a therapeutic regimen for AD and
MCI. The negative correlation with neuropsychological parameters,
i.e., MoCA and HMSE, increases its importance and makes it useful during the clinical setup which is very
needful in developing countries. Peptide YWCS can serve as
a new platform as a 5-LOX inhibitor which can prevent neurotoxicity
developed in AD.